참고문헌
- American Cancer Society. Cancer facts and figures 2001. Am Cancer Soc 2001; 42 p. CeramideTherapy in Prostate Cancer 391
- Dawson N, Moul J, Higano C. Hormonerefractory prostate cancer: Current issues and treatment options. Glenview, IL: Physicians & Scientists Publishing Co., Inc; 1999. 45 p.
- Isaacs JT. Apoptosis: Translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000;92:1367-1369 https://doi.org/10.1093/jnci/92.17.1367
- Ripple GH, Wilding G. Drug development in prostate cancer. Semin Oncol 1999;26:217-226
- Green DR. Apoptotic pathways: Paper wraps stone blunts scissors. Cell 2000;102:1-4 https://doi.org/10.1016/S0092-8674(00)00003-9
- Cattaneo-Pangrazzi RMC, Schott H, Wunderli-Allenspach H, Rothen-Rutishauser B, Guenthert M, Schwendener RA. Cell cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCyd-Pam-P-FdUrd in DU-145 human prostate cancer cells. J Cancer Res Clin Oncol 2000;126:247-256 https://doi.org/10.1007/s004320050339
- Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21:485-495 https://doi.org/10.1093/carcin/21.3.485
- Wang XZ, Beebe JR, Pwiti L, Bielawska A, Smyth MJ. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res 1999;59:5842-5848
- Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 1994;5:391-400
- Tang DG, Porter AT. Target to apoptosis: A hopeful weapon for prostate cancer. Prostate 1997;32:284-293 https://doi.org/10.1002/(SICI)1097-0045(19970901)32:4<284::AID-PROS9>3.0.CO;2-J
-
HS Lee, HS Song. Bee venom inhibits LNCaP cell proliferation through induction of apoptosis via inactivation of NF-
$\kappa$ B. journal of acupuncture and moxibustion 2007;25(2):59-74 - Huggins C, Hodges CV. Studies on prostate cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297
- Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004;61:332-353 https://doi.org/10.1002/pros.20115
- Feldman, B.J., Feldman, D., 2001. The development of androgen independent prostate cancer. Nat. Rev. Cancer 1, 34-45 https://doi.org/10.1038/35094009
- Hiroshi Miyamoto, Saleh Altuwaijri, Yi Cai, Edward M. Messing, and Chawnshang Chang. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Molecular carcinogenesis (2005);44:1-10 https://doi.org/10.1002/mc.20121
- Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A. Androgen receptor: An overview. Crit Rev Eukaryot Gene Expr (1995) 5:97-125 https://doi.org/10.1615/CritRevEukarGeneExpr.v5.i2.10
- Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou QP. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol (2008);217(3):569-76 https://doi.org/10.1002/jcp.21565
- Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:48595
- Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004;91:7099
- Gurumurthy S, Vasudevan KM, Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001;20:22543
- Kantoff PW. New agents in the therapy of hormone-refractory patients with prostate cancer. Semin Oncol 199522 (1 Suppl 1):324
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J Clin 57:43-66 https://doi.org/10.3322/canjclin.57.1.43
- Heinlein CA, Chang C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25:276-308 https://doi.org/10.1210/er.2002-0032
- Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A. 1995. Androgen receptor: An overview. Crit Rev Eukaryot Gene Expr 5:97-125 https://doi.org/10.1615/CritRevEukarGeneExpr.v5.i2.10
- Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y,Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H. 2007. Molecular features of hormonerefractory prostate cancer cells by genomewide gene expression profiles. Cancer Res 67:5117-5125 https://doi.org/10.1158/0008-5472.CAN-06-4040
- W Zhu, PE Murtha, CY Young, Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. Biochem Biophys Res Commun (1995) 214:1130-7 https://doi.org/10.1006/bbrc.1995.2403
- Simon,H.U., Haj-Heyia,A. and Levi Schaffer, F. (2000) Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis, 5, 415-418 https://doi.org/10.1023/A:1009616228304
- Wyllie,A.H. (1995) The genetic regulation of apoptosis. Curr. Opin. Genet.Dev., 5(1), 97-104 https://doi.org/10.1016/S0959-437X(95)90060-8
- Green,D.R. and Reed,J.C. (1998) Mitochondria and Apoptosis. Science, 281,1309-1312 https://doi.org/10.1126/science.281.5381.1309
- Kerr JFR, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;27:2013-2026
- Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336 https://doi.org/10.1038/348334a0
- Lu QL, Abel P, Foster CS, Lalani EN: Bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol 1996;27:102-110 https://doi.org/10.1016/S0046-8177(96)90362-7
- Lane DP: p53, guardian of the genome. Nature 1992;358:15-16 https://doi.org/10.1038/358015a0
- Kernohan NM, Cox LS: Regulation of apoptosis by Bcl-2 and its related proteins: Immunochemical challenges and therapeutic implications. J Pathol 1996;179:1-3 https://doi.org/10.1002/(SICI)1096-9896(199605)179:1<1::AID-PATH509>3.0.CO;2-E
- Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 1996;88:386-401
- Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614-620 https://doi.org/10.1038/nm0697-614
- Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-1565
- Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400
- McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944
- Apakama I, Robinson MC, Walter NM, Charlton RG, Fuller CE, Neal DE, Hamdy FC: bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996;74:1258-1262 https://doi.org/10.1038/bjc.1996.526
- Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53 https://doi.org/10.1126/science.1905840
- Bauer JJ, Sesterhenn IA, Mostofi FK, Mcleod DG, Srivastava S, Moul JE: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511-1516 https://doi.org/10.1016/S0022-5347(01)65641-6
- Moul JW, Bettencourt M-C, Sesterhenn IA, Mostofi FK, McLeod DG, Sristava S, Bauer JJ: Protein expression of p53, bcl-2 and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120: 159-167 https://doi.org/10.1016/S0039-6060(96)80283-2
- Thornberry,N.A. and Lazbrik,Y. (1998) Caspases : enemies within. Science, 281,1312-1316 https://doi.org/10.1126/science.281.5381.1312
- Darmon,A.J., Nicholson,D.W. and Bleackley, R.C. (1995) Activation of the apoptotic proteaseCPP32 by cytotoxic T cell derived granzyme B. Nature, 377,446-448 https://doi.org/10.1038/377446a0
- Stattin P, Damber J-E, Karlberg L, Bergh A: Cell proliferation assessed by KI-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997; 157:219-222 https://doi.org/10.1016/S0022-5347(01)65330-8
- Wyllie,A.H. (1995) The genetic regulation of apoptosis. Curr. Opin. Genet.Dev., 5(1), 97-104 https://doi.org/10.1016/S0959-437X(95)90060-8
- Raj GV, Sekula JA, Guo R, Madden JF, Daaka Y. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. Prostate 2004;61:10513
- Syrovets T, Gschwend JE, Buchele B, et al. Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 2005;280:617080
- Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway.Clin. Cancer Res 2002;8:236977
- Park HJ, Lee YK, Song HS, Kim KJ, Son DJ, Lee JW and Hong JT. Melittin inhibits human prostate cancer cell growth through induction of apoptotic cell death.J. Toxicol. Pub. Health 2006;22(1):31-37.17
-
Park HJ, Lee SH, Son DJ, Oh KW, Kim KH, Song HS, Kim GJ, Oh GT, Yoon DY, and Hong JT. Antiarthritic effect of bee venom: inhibition of Inflammation mediator generation by suppression of NF-
$\kappa$ B through interaction with p50 subunit. Arthritis Rheum 2004;50:3504-15 https://doi.org/10.1002/art.20626
피인용 문헌
- A case report of monitoring PSA level changes in two prostate cancer patients treated with Mountain Ginseng Pharmacopuncture and Sweet Bee Venom along with western anticancer therapy vol.14, pp.4, 2011, https://doi.org/10.3831/KPI.2011.14.4.081